ROVI held its Capital Markets Day where it explained to investors and analysts its strategic vision on the evolution of the business, its R&D plans and the main financial figures. It highlights the operating income forecast for this year, which stands at between 588 and 609 million euros, which would bring forward the achievement of the 2023 target by two years.
Another of the main developments announced at this meeting was the resumption of the regulatory process for Risperidone ISM in Europe, following the successful repetition of the clinical bioavailability study and the submission of the information to the European Medicines Agency.
In front of approximately 60 investors or representatives of investment groups, Juan López-Belmonte, President and CEO of ROVI, reviewed what will be its growth drivers for 2022:
- Low molecular weight heparins, bemiparin and the biosimilar enoxaparin.
- Distribution licensing agreements, such as Neparvis® and Volutsa®.
- The existing portfolio of speciality pharmaceuticals
- The agreement with Moderna for the manufacture of the COVID-19 vaccine.
- New contracts in the area of third-party manufacturing.
This will be accompanied by a high level of investment in the international arena, with the aim of reaching a presence in 120 countries in the coming years and a sales team specialising in the psychiatric area in Europe, as well as the consolidation of the new plant for the active ingredient Low Molecular Weight Heparins in Granada and the new Moderna manufacturing lines.